Allogeneic Tumor Cell Lysate for Dendritic Cell Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malignant pleural mesothelioma are ineffective, and autologous tumor cell-based immunotherapy faces challenges due to limited tumor material availability, variability in tumor cell lysates, and labor-intensive preparation processes, making it difficult to induce robust anti-tumor immune responses.
Innovation Solution
The use of an allogeneic mesothelioma tumor cell lysate prepared from multiple cell lines to load dendritic cells, which increases antigen diversity and standardization, allowing for easier production and quality control, and enabling broader immune recognition of tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous tumor cell lysate is used to load dendritic cells, then patient-specific immune response is improved, but tumor material availability and preparation complexity worsen
Solution Approach 1:
The patent uses allogeneic tumor cell lines as copies or substitutes for patient-specific autologous tumor cells. Instead of requiring actual patient tumor material, standardized allogeneic cell lines expressing mesothelioma-associated antigens are used to load dendritic cells, thereby simplifying preparation while maintaining immunogenicity
Solution Approach 2:
The patent changes the source parameter from autologous (patient-specific) to allogeneic (donor-derived) tumor cells. This parameter change enables standardized production protocols and eliminates the need for individualized tumor material collection and processing, while still achieving effective immune responses through expression of key mesothelioma antigens
2Adaptability or versatility
If autologous tumor cell lysate is prepared for each patient, then personalized treatment is improved, but production time and labor requirements worsen
Solution Approach 1:
Standardized allogeneic tumor cell lines serve as reusable templates that can be produced once and used for multiple patients. This eliminates the need to prepare unique lysates for each patient, dramatically improving production efficiency while maintaining treatment adaptability through antigen-specific immune activation
Solution Approach 2:
The allogeneic tumor cell lines possess universal applicability across multiple patients. A single cell line or panel of cell lines can be used to treat different patients with mesothelioma, enabling standardized manufacturing processes while still providing personalized immunotherapy through dendritic cell loading and patient-specific immune system activation
3Reliability
If limited tumor material is used from resected specimens, then patient-specific antigens are improved, but antigen diversity and immune response robustness worsen
Solution Approach 1:
The patent merges the advantages of both autologous and allogeneic approaches by using allogeneic cell lines that are engineered or selected to express multiple mesothelioma-associated antigens. This combination provides broad antigen diversity similar to patient-specific tumors while enabling standardized production and quality control
Solution Approach 2:
The patent creates a composite immunogenic lysate that combines antigens from multiple allogeneic tumor cell lines or uses single cell lines engineered to express multiple antigens. This composite approach ensures robust immune responses by presenting diverse tumor-associated antigens to the patient's immune system, overcoming the limited antigen diversity from small biopsies
Data Source
AI summary
The present invention relates to a method for the preparation of an immunogenic lysate from mesothelioma tumor cells, to such a lysate and to dendritic cells loaded with the lysate, the present invention further relates a pharmaceutical composition comprising such lysate or dendritic cells, to the use of the lysate, and to said loaded dendritic cells or said pharmaceutical composition for use in the prevention or treatment of mesothelioma.